知识

human health laboratory

Immunogenicity and safety of an Omicron XBB.1.16 adapted vaccine for COVID-19: Interim results from a randomized, controlled, non-inferiority clinical trial

Preclinical evaluation of a COVID19 vaccine

Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2

About RBDCOV Talks

RBDCOV Talks HIPRA’s participation: In 5 minutes, what is a recombinant protein vaccine?

HIPRA R&D Projects

Humoral immune response against XBB.1.5 and BQ.1.1 SARS-CoV-2 variants of a fourth dose of PHH-1V vaccine in adult subjects

RBDCOV

RBDCOV: The project’s origins and future endeavours

HIPRA R&D Projects

Reactogenicity of third and fourth booster doses of HIPRA PHH-1V, a bivalent recombinant protein vaccine against SARS-CoV-2

Laboratory technician of R&D_HIPRA

Humoral immune response against SARS-CoV-2 variants of PHH-1V booster vaccine in subjects previously vaccinated with a mRNA vaccine

One-year humoral response of PHH-1V booster vaccine in subjects previously vaccinated against COVID-19 with a mRNA vaccine. Results of a pivotal randomised controlled trial

One-year humoral response of PHH-1V booster vaccine in subjects previously vaccinated against COVID-19 with a mRNA vaccine

Alex Soriano

Dr. Àlex Soriano (Hospital Clínic de Barcelona): "Public-private collaboration is essential to achieve significant scientific advances"